project id: TCGA-UCEC; case submitter id: TCGA-AX-A3G6; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 8.1; age at index: 67; days to birth: -24681; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1943; age at diagnosis: 24681; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 8.0; figo stage: Stage IA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 456; initial weight: 50.0; oct embedded: false; preservation method: Unknown; sample id: 576ab148-2110-4f35-948a-4a0d00b4f48e; sample submitter id: TCGA-AX-A3G6-01A; portion id: cdc0f4f0-e01a-48f4-8455-2f9a1c7d3ffa; portion submitter id: TCGA-AX-A3G6-01A-11; slide id: ee2cd7d4-0275-40b5-a6cd-d103bfcd811c; slide submitter id: TCGA-AX-A3G6-01A-01-TS1; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 8.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 2.0; percent tumor cells: 90.0; percent tumor nuclei: 94.0; section location: TOP;